<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03592836</url>
  </required_header>
  <id_info>
    <org_study_id>DRAIN trial</org_study_id>
    <nct_id>NCT03592836</nct_id>
  </id_info>
  <brief_title>Diuretic Response in Advanced Heart Failure: Bolus Intermittent vs Continuous INfusion</brief_title>
  <acronym>DRAIN</acronym>
  <official_title>Diuretic Treatment in High Risk Decompensated Advanced Heart Failure. Bolus Intermittent Versus Continuous Infusion of Furosemide: a Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turin, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Turin, Italy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Loop diuretics are the main therapy for decongestion of patients with advanced acute heart
      failure. However, these patients often develop diuretic-resistance or even
      diuretic-refractoriness. In order to overcome such resistance to diuretic, the clinician can
      increase the dose of furosemide, or change the way of administration (continuous infusion
      versus boluses) or associate a different class of diuretics (thiazide diuretics, K+-sparing
      diuretics) up to the addition of low doses of inotropic agents to improve renal perfusion. At
      the present time there is no evidence in literature in advanced acute heart failure patients
      about the superiority of the treatment with furosemide in continuous infusion or in
      intermittent boluses. The aim of the study was to evaluate the efficacy of furosemide in
      boluses versus continuous infusion in advanced acute heart failure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2013</start_date>
  <completion_date type="Actual">December 22, 2017</completion_date>
  <primary_completion_date type="Actual">December 22, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from congestion</measure>
    <time_frame>72 hours after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Worsening of renal function</measure>
    <time_frame>72 hours after randomization</time_frame>
    <description>Increase in creatinine value &gt; 0.3 mg/dl or increase &gt; 1.5 times</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worsening or persistent HF at 72 h</measure>
    <time_frame>72 hours after randomization</time_frame>
    <description>Need to increase the dose of inotropes or diuretics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>72 hours after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory data variations in NTproBNP</measure>
    <time_frame>72 hours after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>72 hours after randomization</time_frame>
    <description>Composed by the following events: persistence of congestion, need to increase diuretic treatment, need of renal replacement treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight differences based on diuretic dose unity</measure>
    <time_frame>72 hours after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Heart Failure NYHA Class III</condition>
  <condition>Heart Failure NYHA Class IV</condition>
  <arm_group>
    <arm_group_label>Continuous infusion of loop diuretics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Furosemide continuous infusion: 125 or 250 mg die</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermittent infusion of loop diuretics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Furosemide bolus intermittent: 125 or 250 mg die</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loop Diuretics</intervention_name>
    <description>intravenous administration of diuretics</description>
    <arm_group_label>Continuous infusion of loop diuretics</arm_group_label>
    <arm_group_label>Intermittent infusion of loop diuretics</arm_group_label>
    <other_name>furosemide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced heart failure

          -  WET ≥ 12

          -  Systolic blood pressure ≤ 110 mmHg

          -  Serum sodium ≤ 135 mEq/L

          -  Left systolic ventricular insufficiency (FE &lt; 35%) note for at least 6 months

          -  Class NYHA III-IV despite medical treatment maximal

        Exclusion Criteria:

          -  Acute coronary syndrome

          -  Shock cardiogenic

          -  Chronic renal failure stage V
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simone Frea, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.O.U. Città della Salute e della Scienza di Torino</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Simone Frea</name>
      <address>
        <city>Torino</city>
        <state>To</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 18, 2018</study_first_submitted>
  <study_first_submitted_qc>July 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2018</study_first_posted>
  <last_update_submitted>July 9, 2018</last_update_submitted>
  <last_update_submitted_qc>July 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Turin, Italy</investigator_affiliation>
    <investigator_full_name>Simone Frea</investigator_full_name>
    <investigator_title>MD, Cardiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Sodium Potassium Chloride Symporter Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

